Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Increased protein expression of interleukin-10 and its signalling molecules in colon cancer progression: potential prognostic and therapeutic targets.Discover oncology · 2025
   Article
2. Differential Effects of High-Fiber and Low-Fiber Diets on Antitumor Immunity and Colon Tumor Progression in a Murine Model.Cancer prevention research (Philadelphia, Pa.) · 2025
   Article
3. TP53TG1/STAT axis is involved in the development of colon cancer through affecting PD-L1 expression and immune escape mechanism of tumor cells.American journal of cancer research · 2023
   Article
4. Molecular Characterization of Primary and Metastatic Colon Cancer Cells to Identify Therapeutic Targets with Natural Compounds.Current topics in medicinal chemistry · 2022
   Article
5. Identification and Validation of Novel Immune-Related Alternative Splicing Signatures as a Prognostic Model for Colon Cancer.Frontiers in oncology · 2022
   Article
6. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.Leukemia · 2021
   Article
7. Establishment and verification of a prognostic tumor microenvironment-based and immune-related gene signature in colon cancer.Journal of gastrointestinal oncology · 2021
   Article
8. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy.Advanced healthcare materials · 2021
   Review
9. Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment.Oncoscience · 2021
   Article
10. YYFZBJS inhibits colorectal tumorigenesis by remodeling gut microbiota and influence on M2 macrophage polarizationAmerican journal of cancer research · 2021
    Article
11. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.Endocrinology · 2020
    Article
12. Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis.Annals of translational medicine · 2020
    Article
13. Chemoprevention of Colorectal Cancer by Anthocyanidins and Mitigation of Metabolic Shifts Induced by Dysbiosis of the Gut Microbiome.Cancer prevention research (Philadelphia, Pa.) · 2020
    Article
14. In vivo tracking of orally-administered particles within the gastrointestinal tract of murine models using multispectral optoacoustic tomography.Photoacoustics · 2019
    Article
15. IFNβ-producing CX3CR1Oncoimmunology
    Article
16. Enhanced gut barrier integrity sensitizes colon cancer to immune therapy.Oncoimmunology
    Article
17. Intravaginal Administration of Interleukin 12 during Genital Gonococcal Infection in Mice Induces Immunity to Heterologous Strains ofmSphere
    Article
18. Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8Oncoimmunology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as